Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03628677 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
A Phase 1 study of Solid Tumor, Unspecified, Adult, sponsored by Arcus Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 10
- Study locations
NCT03628677: Completed Phase 1 study of Solid Tumor, Unspecified, Adult, sponsored by Arcus Biosciences.
NCT03628677 is a Phase 1 study of Solid Tumor, Unspecified, Adult that has completed, run by Arcus Biosciences. The registered enrollment target is 75 participants, below the 172-participant average among 6 other Solid Tumor, Unspecified, Adult trials with a reported enrollment target (56% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03628677, a Phase 1 study of Solid Tumor, Unspecified, Adult, has completed, sponsored by Arcus Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab (AB154) as monotherapy and in combination with zimberelimab (AB122) in participants with advanced solid malignancies.
Primary Outcome
Number of Participants Treated with domvanalimab or domvanalimab in Combination with zimberelimab with Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0
Conditions Studied
Interventions
- DRUG Zimberelimab
- DRUG Domvanalimab
Study Locations (10)
Texas
- MD Anderson Cancer Center - Houston
- START - San Antonio
New South Wales
- The Kinghorn Cancer Centre - St Vincent Public Hospital - Darlinghurst
- Tweed Hospital - Tweed Heads
California
- The Angeles Clinic and Research Institute - Los Angeles
Illinois
- Affinity Health-Hope and Healing Cancer Services, LLC - Hinsdale
North Carolina
- Carolina BioOncology Institute - Huntersville
Washington
- Medical Oncology Associates, PS (dba Summit Cancer Centers) - Spokane
Queensland
- Icon Cancer Care Brisbane - South Brisbane
Victoria
- Olivia Newton-John Cancer Research Institute-Austin Hostipal - Heidelberg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2018-09-12 |
| Est. Completion | 2025-01-23 |
| Phase | Phase 1 |
What the finished NCT03628677 record still lists
NCT03628677 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 172-participant average among 6 other Solid Tumor, Unspecified, Adult trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Solid Tumor, Unspecified, Adult appearing as the primary indexed condition, and to 2 interventions - of which Zimberelimab is the first listed.
NCT03628677 lists 10 locations in 8 states (Texas, New South Wales, California).
Frequently Asked Questions
What is clinical trial NCT03628677 about?
NCT03628677 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies". This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab (AB154) as monotherapy and in combination with zimberelimab (AB122) in participants with advanced solid malignancies.
What is the current status of trial NCT03628677?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2018-09-12. Estimated completion is 2025-01-23.
What conditions does trial NCT03628677 study?
This clinical trial studies the following conditions: Solid Tumor, Unspecified, Adult.
What interventions are being tested in trial NCT03628677?
The interventions under investigation include: Zimberelimab (DRUG), Domvanalimab (DRUG).
Who is sponsoring clinical trial NCT03628677?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03628677 being conducted?
This trial has 10 study locations across California, Illinois, North Carolina, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Unspecified, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
COMPLETED · Phase 1
-
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
RECRUITING · NA
-
Psychotherapy Intervention for Latinos With Adv Cancer
RECRUITING · NA
-
Psychotherapy Intervention for Latinos With Advanced Cancer
RECRUITING · NA
-
Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI